]>
IRCT20220720055510N1 IRCT 2022-07-30 Shahre-kord University of Medical Sciences The effect of Liraglutide on clinical and paraclinical symptoms in patients with polycystic ovary syndrome The effect of Liraglutide on clinical and paraclinical symptoms in patients with polycystic ovary syndrome with high body mass index in patients referred to Shahrekord endocrinology clinics 2022-08-08 anticipated 35 Complete https://irct.ir/trial/64923 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Poly cystic ovary syndrom. Intervention group: patients with polycystic ovary syndrome with high body mass index referred to Shahrekord endocrinology clinics who are treated with liraglutide drug under the brand name Victoza from Novonordisk pharmaceutical company. Liraglutide drug is used subcutaneously at a dose of 0.6 mg in the first week, 1.2 mg in the second week, and then 1.8 mg in the third week until the end of three months.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.
public Fariba mansouri
Internal medicine group office, Hajar hospital, Parastar Ave.
Shahrekord Iran (Islamic Republic of) 8815854459 +98 38 3352 2940 Dr.f.mansouri.1393@gmail.com Shahre-kord University of Medical Sciences scientific Mahboube taghipour
Internal medicine group office, Hajar hospital, Parastar Ave.
Shahrekord Iran (Islamic Republic of) 8815854459 +98 38 3352 2940 Taghipour.m@skums.ac.ir Shahre-kord University of Medical Sciences Iran (Islamic Republic of) Women with polycystic ovary syndrome between the ages of 18 and 45 years, Written and oral consent is obtained from patients to participate in the study Do not have chronic physical diseases (except polycystic ovary syndrome) and mental diseases. According to the patient, there is no long-term use of drugs. Body mass index is more than 25 kg/m2. 18 years 45 years Female Smoke. suffering from other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor. Taking drugs that lead to side effects such as menstrual disorders, hirsutism or acne, or affect the profile of fat or blood sugar in the last 3 months, such as OCP, thiazides, corten, metformin, etc. be pregnant. Menopause Have a history of previous pancreatitis. Have a family history of medullary thyroid carcinoma (mtc). E28.2 Polycystic ovarian syndrome Treatment - Drugs Intervention group: patients with polycystic ovary syndrome with high body mass index referred to Shahrekord endocrinology clinics who are treated with liraglutide drug under the brand name Victoza from Novonordisk pharmaceutical company. Liraglutide drug is used subcutaneously at a dose of 0.6 mg in the first week, 1.2 mg in the second week, and then 1.8 mg in the third week until the end of three months. Fasting insulin. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory. Fasting blood glucose. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory. Menstruation. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Patient History. Hirsutism. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Ferriman-Gallwey scoring system, observation. Acne. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Observation. TG,HDL,LDL. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory. Weight. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Scale. Hair loss. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Patient history. Shahre-kord University of Medical Sciences Approved 2022-06-14 Ethics committee of shahrekord University of Medical Sciences shahrekord University of Medical Sciences, kashani Blvd. Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)